TY - JOUR
T1 - Noninvasive Glioblastoma Testing
T2 - Multimodal Approach to Monitoring and Predicting Treatment Response
AU - Verduin, Maikel
AU - Compter, Inge
AU - Steijvers, Danny
AU - Postma, Alida A.
AU - Eekers, Danielle B. P.
AU - Anten, Monique M.
AU - Ackermans, Linda
AU - ter Laan, Mark
AU - Leijenaar, Ralph T. H.
AU - van de Weijer, Tineke
AU - Tjan-Heijnen, Vivianne C. G.
AU - Hoeben, Ann
AU - Vooijs, Marc
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Glioblastoma is the most aggressive adult primary brain tumor which is incurable despite intensive multimodal treatment. Inter- and intratumoral heterogeneity poses one of the biggest barriers in the diagnosis and treatment of glioblastoma, causing differences in treatment response and outcome. Noninvasive prognostic and predictive tests are highly needed to complement the current armamentarium. Noninvasive testing of glioblastoma uses multiple techniques that can capture the heterogeneity of glioblastoma. This set of diagnostic approaches comprises advanced MRI techniques, nuclear imaging, liquid biopsy, and new integrated approaches including radiogenomics and radiomics. New treatment options such as agents targeted at driver oncogenes and immunotherapy are currently being developed, but benefit for glioblastoma patients still has to be demonstrated. Understanding and unraveling tumor heterogeneity and microenvironment can help to create a treatment regime that is patient-tailored to these specific tumor characteristics. Improved noninvasive tests are crucial to this success. This review discusses multiple diagnostic approaches and their effect on predicting and monitoring treatment response in glioblastoma.
AB - Glioblastoma is the most aggressive adult primary brain tumor which is incurable despite intensive multimodal treatment. Inter- and intratumoral heterogeneity poses one of the biggest barriers in the diagnosis and treatment of glioblastoma, causing differences in treatment response and outcome. Noninvasive prognostic and predictive tests are highly needed to complement the current armamentarium. Noninvasive testing of glioblastoma uses multiple techniques that can capture the heterogeneity of glioblastoma. This set of diagnostic approaches comprises advanced MRI techniques, nuclear imaging, liquid biopsy, and new integrated approaches including radiogenomics and radiomics. New treatment options such as agents targeted at driver oncogenes and immunotherapy are currently being developed, but benefit for glioblastoma patients still has to be demonstrated. Understanding and unraveling tumor heterogeneity and microenvironment can help to create a treatment regime that is patient-tailored to these specific tumor characteristics. Improved noninvasive tests are crucial to this success. This review discusses multiple diagnostic approaches and their effect on predicting and monitoring treatment response in glioblastoma.
KW - POSITRON-EMISSION-TOMOGRAPHY
KW - HIGH-GRADE GLIOMAS
KW - MAGNETIC-RESONANCE-SPECTROSCOPY
KW - NEUROONCOLOGY WORKING GROUP
KW - POTENTIAL SERUM BIOMARKERS
KW - FUNCTIONAL DIFFUSION MAP
KW - TRUE TUMOR PROGRESSION
KW - BRAIN-TUMORS
KW - RECURRENT GLIOMA
KW - DIAGNOSTIC-ACCURACY
U2 - 10.1155/2018/2908609
DO - 10.1155/2018/2908609
M3 - (Systematic) Review article
C2 - 29581794
SN - 0278-0240
VL - 2018
JO - Disease Markers
JF - Disease Markers
M1 - 2908609
ER -